Filtered By:
Management: Partnerships
This page shows you your search results in order of date.
Order by Relevance | Date
Total 212 results found since Jan 2013.
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Ghana: Benemef Foundation Donates Gh¢60,000 Wheel Chairs ...Walking Sticks to Stroke Patients
[Ghanaian Times] Benemef Foundation, a non-governmental organisation (NGO), in partnership with Dr Wanda Evans-Brewer, a philanthropist, have presented 58 wheel chairs and walking sticks valued at more than GH¢60,000 to stroke patients and people living with disabilities in three communities in the Greater Accra and Volta regions respectively.
Source: AllAfrica News: Health and Medicine - August 25, 2023 Category: African Health Tags: Aid and Assistance Ghana Health and Medicine West Africa Source Type: news
Qure.ai highlights clinical results from chest x-ray software study
Radiology AI software developer Qure.ai is highlighting results from a stud...Read more on AuntMinnie.comRelated Reading:
Qure.ai partners with Blackford in U.K.
Qure.ai wins Japan QuickFire challenge
Qure.ai joins forces with Nuance
Medtronic and Qure.ai partner to advance AI stroke management
Qure.ai, Therapixel enter into distribution partnership
Source: AuntMinnie.com Headlines - August 7, 2023 Category: Radiology Source Type: news
Qure.ai partners with Blackford in U.K.
Radiology AI software developer Qure.ai is partnering with Blackford, usin...Read more on AuntMinnie.comRelated Reading:
Qure.ai wins Japan QuickFire challenge
Qure.ai joins forces with Nuance
Medtronic and Qure.ai partner to advance AI stroke management
Qure.ai, Therapixel enter into distribution partnership
Qure.ai secures EU medical device regulation certification
Source: AuntMinnie.com Headlines - August 2, 2023 Category: Radiology Source Type: news
Qure.ai partners with Blackford
Radiology AI software developer Qure.ai is partnering with Blackford, usin...Read more on AuntMinnie.comRelated Reading:
Qure.ai wins Japan QuickFire challenge
Qure.ai joins forces with Nuance
Medtronic and Qure.ai partner to advance AI stroke management
Qure.ai, Therapixel enter into distribution partnership
Qure.ai secures EU medical device regulation certification
Source: AuntMinnie.com Headlines - August 1, 2023 Category: Radiology Source Type: news
Aidoc launches updates to its stroke identification software
Clinical AI firm Aidoc has released updates to its Full Brain Solution, an acut...Read more on AuntMinnie.comRelated Reading:
Aidoc to partner with Northwell Health
Aidoc's algorithms go live in Epic's App Orchard
Ken. health system to implement AI software from Aidoc
Aidoc raises $110M
Aidoc adds x-ray AI tool via partnership with Gleamer
Source: AuntMinnie.com Headlines - July 31, 2023 Category: Radiology Source Type: news
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Qure.ai wins Japan QuickFire challenge
AI radiology software company Qure.ai has won the Japan Smart Healthy Agin...Read more on AuntMinnie.comRelated Reading:
World record achieved for x-ray at highest altitude
Qure.ai joins forces with Nuance
Medtronic and Qure.ai partner to advance AI stroke management
AI helps improve TB screening in Nigeria
Qure.ai, Therapixel enter into distribution partnership
Source: AuntMinnie.com Headlines - July 5, 2023 Category: Radiology Source Type: news
New Urban Health ‘Accelerator’ Aims to Transform Cardiovascular Population Health Globally
ihadmin2May 22, 2023May 22, 2023GenevaThe CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.Results of initial programs in S ão Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% of heart attacks during implementation.Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world ’s leading cause of death,according to the World Health O...
Source: IntraHealth International - May 22, 2023 Category: International Medicine & Public Health Authors: ihadmin2 Source Type: news
Stroke services, training, research and advocacy needs in Africa: Preliminary results from the Africa – UK Stroke Partnership (AUKSP) project
We describe the status of acute stroke care services and unmask training and research needs in Africa.
Source: Journal of Stroke and Cerebrovascular Diseases - March 30, 2023 Category: Neurology Authors: Olaleye Adeniji, Stephanie Jones, Joseph Spencer, Gabriel Ogunde, Joseph Yaria, Pamela Naidoo, Foad Abdallah, Philip Adebayo, Paul Macaire Ossou-Nguiet, Dorcas Ogunloye, Jennifer Edwards, Liz Lightbody, Mayowa Owolabi, Caroline Watkins, Rufus Akinyemi, AU Source Type: research
Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
AbstractPurpose of ReviewTesticular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) i ncluding myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may furth...
Source: Current Oncology Reports - March 3, 2023 Category: Cancer & Oncology Source Type: research
ASOC Osuntokun Award Lecture 2022: Partnership for stroke prevention and treatment in Africa: Qualitative research processes and findings
Africa has one of the highest rates of stroke and stroke deaths in the world. The burden of stroke is increasing with a 3-year mortality rate of up to 84%. Stroke disproportionately affects the young and middle-aged population contributing to morbidity and mortality affecting families, communities, health systems, and economic progress. My objectives of the 2022 Osuntokun Award Lecture at the African Stroke Organization Conference were to explore our qualitative research findings from our communities and to propose future qualitative methods for improving stroke outcomes in Africa.
Source: Journal of Stroke and Cerebrovascular Diseases - March 2, 2023 Category: Neurology Authors: Carolyn Jenkins Source Type: research
